Type 2 Diabetes – Geographic Focus: China – Type 2 Diabetes | China In-Depth | China – 2021
Type 2 diabetes (T2D) remains one of the biggest health challenges in China, where the prevalence of disease is globally the highest. Several traditional drug classes such as biguanides and alpha-glucosidase inhibitors have enjoyed a high patient uptake in China owing to their long-standing market presence, physician comfort, and reimbursement through Category A of the NRDL. The dynamic access and reimbursement landscape of China has bolstered the uptake of newer drug classes—SGLT-2 inhibitors (such as dapagliflozin, canagliflozin, empagliflozin), GLP-1 receptor agonists (such as dulaglutide), and insulins (such as insulin degludec/insulin aspart)—through the inclusion of several high-performing agents in recent NRDL updates. Thus, the T2D market of China is expected to expand further over the 2020-2030 period, fueled by the increasing disease prevalence and an increasing uptake of novel agents that will boost overall market sales.
QUESTIONS ANSWERED
- How large is China’s drug-treatable T2D population, and how will the drug-treatment rate change during the forecast period?
- Which are the most commercially relevant drugs in China’s T2D market and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
- What are the market access considerations for key therapies in the T2D pipeline in China? What sales / uptake could they secure in T2D? What are interviewed experts’ opinions of key emerging therapies?
- What are the key drivers and constraints in the Chinese T2D market, and how will the market evolve over the forecast period?
PRODUCT DESCRIPTION
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Release Date
July 2021
Geographies
China
Primary Research
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and surveys with 50 endocrinologists
Epidemiology
Diagnosed prevalence of T2D by country, with urban and rural breakup. Clinically relevant and market-relevant drug-treatable populations.
Forecast
10-year, annualized, drug-level sales and patient share of key T2D therapies through 2030, based on primary and secondary market research to formulate bottom-up assumptions
Emerging Therapies
Phase III/PR: 10+ drugs; Phase II: 5+ drugs; coverage of select preclinical and Phase I products
Karan Verma, M.Sc., is a lead healthcare research and data analyst on the China In-Depth team at Clarivate. He is involved in primary and secondary market research to create syndicated landscape and forecast content and provide Chinese market-specific insights in various therapy areas, including CAR T-cell therapies, prostate cancer, hepatocellular carcinoma, multiple myeloma, non-Hodgkin’s lymphoma, migraine, type 2 diabetes, and multiple sclerosis. He has expertise in market forecasting, competitive intelligence, benchmarking, and brand performance analytics. He obtained his M.Sc. in biomedical engineering from the University of Warwick in Coventry, United Kingdom, and a B.E. in biomedical engineering from Maharshi Dayanand University in Haryana, India.